Monocyte subsets and their phenotypes during treatment with BCR‐ABL1 tyrosine kinase inhibitors for Philadelphia chromosome‐positive leukemia

• Published in: Hematological oncology Vol. 36; no. 2; pp. 451 - 456
• Main Authors: Konuma, Takaaki, Kohara, Chisato, Watanabe, Eri, Mizukami, Motoko, Nagai, Etsuko, Tanoue, Susumu, Isobe, Masamichi, Jimbo, Koji, Kato, Seiko, Ohno, Nobuhiro, Takahashi, Satoshi, Tojo, Arinobu
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.04.2018
• Subjects: Adult; Aged; Aged, 80 and over; BCR-ABL protein; CC chemokine receptors; CCR2 protein; chemokine receptor; Chemokine receptors; Chemokines; CX3CR1 protein; dasatinib; Dasatinib - therapeutic use; Female; Fusion Proteins, bcr-abl - antagonists & inhibitors; Humans; Imatinib; Imatinib Mesylate - therapeutic use; Inhibitors; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Male; Middle Aged; monocyte; Monocyte chemoattractant protein 1; Monocytes; Monocytes - drug effects; Monocytes - metabolism; nilotinib; Patients; Phenotype; Philadelphia chromosome; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Receptors; Receptors, Chemokine - metabolism; scavenger receptor; Scavenger receptors; Scavenger Receptors, Class A - metabolism; Targeted cancer therapy; Tyrosine; Tyrosine kinase inhibitors; vascular event; scavenger receptor; dasatinib; vascular event; nilotinib; imatinib; monocyte; chemokine receptor

BCR‐ABL1 tyrosine kinase inhibitors (TKIs) are effective agents in the treatment of Philadelphia chromosome‐positive leukemia. However, vascular events have developed in some patients receiving each TKI. The perturbation of circulating monocyte subsets and their expressions of chemokine and scavenge...